DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for mitral valve insufficiency — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMitral valve insufficiency maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for mitral valve insufficiency is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
fibrillin 1 (FBN1) — FBN1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1UZK · 1.35 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Mitral valve repair is widely regarded as the optimal surgical procedure for mitral valve dysfunction of all etiologies, with the strongest supporting evidence in degenerative mitral regurgitation. A 1999 study of 68 patients (34 male, age range 17 to 82 years) who underwent surgical mitral valve repair reported a hospital mortality of 4.4% (three patients). Over a mean follow-up of 36.5 months, five more patients died and one required mitral valve replacement. Actuarial survival probability was 95.3% at one year and 83.5% at five years; reoperation-free survival was 100% at one year and 97.4% at five years. Functional capacity improved from a preoperative mean of 2.96 to 1.25 at follow-up. Echocardiography at the end of follow-up showed no mitral insufficiency in 48.4% of patients, minimal insufficiency in 35.5%, mild in 14.5%, and moderate in 1.6%.
For ischemic mitral regurgitation specifically, a 2011 review notes that mitral valve repair has been shown to offer improved short-term and long-term survival, decreased valve-related morbidity, and improved left ventricular function compared with mitral valve replacement. However, the same review states that replacement should be considered for high-risk patients and those with specific underlying mechanisms of ischemic mitral regurgitation, and that in the absence of level one evidence, future randomised prospective clinical trials are needed to directly compare these surgical techniques. A 2015 review similarly concludes that repair is the optimal procedure but that the supporting evidence is strongest in degenerative disease.
A 2020 review describes transcatheter mitral valve repair with a clip as an option for secondary or functional mitral insufficiency, which is common among older patients or those with multiple comorbidities who are often not eligible for conventional surgery. A 2024 review of mitral valve genetics, covering literature up to February 2024, advocates for the importance of a gene-based therapy that should be available soon to prevent or treat valvular degeneration non-invasively, but no such therapy is described in the abstracts. A 2016 case report notes that the pathogenic cause of myxomatous mitral valves has not been elucidated.
What is still missing are randomised prospective clinical trials directly comparing repair and replacement for ischemic mitral regurgitation, a clear genetic or molecular target for non-invasive therapy, and any pharmacological or repurposed drug treatment tested in humans for mitral valve insufficiency.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PubMed · 2015 · 39 citations
Mitral valve repair versus replacement.
AbstractDegenerative, ischemic, rheumatic and infectious (endocarditis) processes are responsible for mitral valve disease in adults. Mitral valve repair has been widely regarded as the optimal surgical procedure to treat mitral valve dysfunction of all etiologies. The supporting evidence for repair over replacement is strongest in degenerative mitral regurgitation. The aim of the present review is to summarize the data in each category of mitral insufficiency and to provide recommendations based upon this data.
Current Opinion in Cardiology · 2011 · 21 citations
Should all ischemic mitral regurgitation be repaired? When should we replace?
AbstractPURPOSE OF REVIEW: Ischemic mitral regurgitation (IMR) is a major source of morbidity and mortality. Although mitral valve repair has become recently popularized for the treatment of IMR, select patients may derive benefits from replacement. The purpose of this review is to describe current surgical options for IMR and to discuss when mitral valve replacement (MVR) may be favored over mitral valve repair. RECENT FINDINGS: Current surgical options for the treatment of IMR include surgical revascularization alone, mitral valve repair, or MVR. Although surgical revascularization alone may benefit patients with mild-moderate IMR, most surgeons advocate the performance of revascularization in combination with either mitral valve repair or replacement. In the current era, mitral valve repair has proven to offer improved short-term and long-term survival, decreased valve-related morbidity, and improved left ventricular function compared with MVR. However, MVR should be considered for high-risk patients and those with specific underlying mechanisms of IMR. SUMMARY: In the absence of level one evidence, mitral valve repair offers an effective and durable surgical approach to the treatment of mitral insufficiency and remains the operation of choice for IMR. MVR, however, is preferred for select patients. Future randomized, prospective clinical trials are needed to directly compare these surgical techniques.
Revista médica de Chile · 1999 · 7 citations · open access
Resultados alejados de la cirugía reconstructora de la insuficiencia mitral
AbstractBACKGROUND: Surgical repair is the procedure of choice for mitral insufficiency since it preserves better left ventricular structure and function. AIM: To assess the long term clinical and echocardiographic results of mitral valve reconstructive surgery. MATERIAL AND METHODS: A review of clinical and echocardiographic data of 68 patients (34 male, age range 17 to 82 years), subjected to surgical mitral valve repair between December 1991 and March 1998. Preoperative functional capacity of these patients was 2.96 +/- 0.7. Surgical repair was assessed using transesophagic echocardiography in all subjects. RESULTS: The etiology of mitral insufficiency was degenerative in 43 patients, rheumatic in 10, infectious in 6, ischemic in 5 and miscellaneous in 4. The most frequent pathological findings were dilatation of the mitral ring in 42% of patients, chordae tendinae rupture in 32% and enlargement in 24%. A mitral anuloplasty was done in 90% of patients, a cuadrilateral resection of posterior leaflet in 52% and chordae tendinae transference in 12%. An additional surgical procedure was done in 34% of subjects. Three patients died during hospitalization (4.4%). During the follow up of 36.5 +/- 22.3 months, five patients died and one required a mitral valve replacement. The actuarial survival probability was 95.3 +/- 2.6% at one year and 83.5 +/- 6.5% at five years. The reoperation free survival was 100% at one year and 97.4 +/- 2.5% at five years. At the end of follow up the functional capacity improved to 1.25 +/- 0.4. Echocardiography showed absence of mitral insufficiency in 48.4% of patients, minimal, mild and moderate insufficiency in 35.5, 14.5 and 1.6% of patients respectively. CONCLUSIONS: Surgical valve reconstruction in mitral insufficiency has satisfactory long term results and should be the procedure of choice for eligible patients.
Pathology - Research and Practice · 2024 · 3 citations · open access
Update on the genetic profile of mitral valve development and prolapse
AbstractThe purpose of this review is to present a comprehensive overview of the literature published up to February 2024 on the PubMed database regarding the development of mitral valve disease, with detailed reference to mitral valve prolapse, from embryology to a genetic profile. Out of the 3291 publications that deal with mitral valve embryology, 215 refer to mitral valve genetics and 83 were selected for further analysis. After reviewing these data, we advocate for the importance of a gene-based therapy that should be available soon, to prevent or treat non-invasively the valvular degeneration.
Polish Journal of Radiology · 2016 · 2 citations · open access
Myxomatous Mitral Valve with Prolapse and Flail Scallop
AbstractBACKGROUND: Myxomatous mitral valve with prolapse are classically seen with abnormal leaflet apposition during contraction of the heart. Hemodynamic disorders can result from eccentric mitral regurgitation usually caused by chordae tendinae rupture or papillary muscle dysfunction. Echocardiography is the gold standard for evaluation of leaflet flail and prolapse due to high sensitivity and specificity. Though most mitral valve prolapse are asymptomatic those that cause severe regurgitation need emergent surgical intervention to prevent disease progression. CASE REPORT: We report a 54 year old Hispanic male who presented with progressively worsening dyspnea and palpitations. Initial evaluation was significant for atrial fibrillation on electrocardiogram with subsequent echocardiography revealing myxomatous mitral valve with prolapse. Following surgical repair of the mitral valve, the dyspnea and palpitations resolved. CONCLUSIONS: Mitral valve prolapse is a common valvular abnormality but the pathogenic cause of myxomatous valves has not been elucidated. Several theories describe multiple superfamilies of proteins to be involved in the process. Proper identification of these severe mitral regurgitation due to these disease valves will help relieve symptomatic mitral valve prolapse patients.
Journal of Transcatheter Interventions · 2020 · 1 citations · open access
Transcatheter mitral valve repair with clip for treatment of secondary or functional mitral insufficiency. Literature review
AbstractMitral insufficiency is one of the most common acquired heart valve diseases and a common cause of heart failure, often in response to mitral annulus dilation. In such cases, the condition is referred to as functional or secondary and may be associated with ischemic heart disease or other dilated cardiomyopathies of varying etiology. Mitral valve insufficiency is common among older patients or individuals with several comorbidities, who are often not eligible for conventional mitral valve surgery due to high [...]
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
